Duvakitug

• Description :

  Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS) . Duvakitug can be used in the study of Crohn's Disease (CD) [1][2].

• Product Name Alternative :

  TEV-48574

• UNSPSC :

  12352203

• Target :

  TNF Receptor

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Apoptosis

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/duvakitug.html

• Purity :

  99.76

• Solubility :

  10 mM in DMSO

• Smiles :

  [Duvakitug]

• Molecular Weight :

  (143.64 kDa)

• References & Citations :

  [1]Duvakitug. IMGT/mAb-DB.|[2]Gonsky, et al. Intestinal mononuclear phagocytes as prognostic biomarker for Crohn's disease. World Intellectual Property Organization, WO2023102051 A1. 2023-06-08.|[3]Reinisch W, et al. OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD) [J]. Journal of Crohn's and Colitis, 2025, 19 (Supplement_1) : i79-i80.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2750005-84-4]